Disclosed herein is a method of detecting the presence or absence of an analyte in a test sample, based on the use of motion resistant particle for example non-magnetic particle coated with first sensing element for the analyte and force driven particle for example superparamagnetic particle coated with a second sensing element for the analyte so as to form a motion resistant particle-analyte-force driven particle conjugate. A viscous medium is added to the mixture and a force such as magnetic force is applied to provide separation of the conjugate for quantification. Disclosed herein are also a sensing kit, a system for detecting the presence or absence of an analyte in a test sample and the use of the kit or the system thereof.

A novel assay which can differentiate a neutralizing antibody from non-neutralizing antibody which can be easily visualized, for example, by a portable UV lamp, among other visualization techniques. This assay can produce results in about 30 minutes and can be performed by untrained individuals in a non-laboratory environment. Also described is an ELISA method for determining if a human possesses at least one type of neutralizing antibody against SARS-Cov-2.

The disclosure belongs to the field of biotechnology, and in particular to a blocking ELISA kit for detecting an antibody to swine acute diarrhea syndrome coronavirus (SADS-CoV) N protein. The kit includes an enzyme plate coated with SADS-CoV N protein, an HRP-labeled mouse anti-SADS-CoV N protein monoclonal antibody (mAb), a positive serum control, and a negative serum control. The kit may detect positive sera diluted at 1:512, with no cross-reaction with positive sera against porcine epidemic diarrhea virus (PEDV), transmissible gasteroenteritis virus (TGEV) and porcine deltacoronavinis (PDCoV) etc., and the intrabatch and interbatch coefficient of variation is less than 10%. The comparison result with the indirect immunofluorescence test shows that the concordance rate of the blocking ELISA kit of the present disclosure is 99.6%, the Kappa value is 0.91, and the blocking ELISA method established by the present disclosure is highly consistent with IFA.

The present invention relates to a composition comprising a probe for detecting six representative causative viruses of acute enteritis (norovirus genogroup I and genogroup II, rotavirus, hepatitis A virus, coxsackievirus, astrovirus, and adenovirus), and a DNA microarray, a kit, and a detection method comprising the composition. The present invention is effective due to high specificity and sensitivity to viruses. In addition, since the causative viruses can simply be detected at low cost compared to conventional detection methods, without expensive diagnosis devices or specialists, the present invention may be effectively used as a method for diagnosing viruses causing acute enteritis.

The present invention relates the field of animal health. Particularly, the present invention relates to a recombinant classical swine fever virus E2 protein in which a fragment comprising at least one of the amino acids defining the 6B8 epitope of the CSFV E2 protein is replaced by a corresponding fragment of the E2 protein from a pestivirus other than CSFV. Further, the present invention provides an immunogenic composition comprising the recombinant E2 protein of the present invention and the use of the immunogenic composition for preventing and/or treating diseases associated with CSFV in an animal. Moreover, the present invention provides a method and a kit for differentiating animals infected with CSFV from animals vaccinated with the immunogenic composition of the present invention.

Recent literature on SARS-CoV-2 pathogenesis has suggested that the induction of substantial acute respiratory distress phenotypes is driven by a mismatched inflammatory response together with broad vascular dysfunction. While several detailed reports implementing multi-omic approaches have provided insight into the immune cell phenotypes involved in these processes, risk stratifying markers specific to COVID-19 and the vasculature have not been explored. Provided herein is a comprehensive, multi-omics-based description of the molecular antecedents to COVID-19 mortality, yielding new insights pertaining to the vasculature while highlighting the urgent need for clinical translation of novel biomarkers for disease prognosis.

A highly specific molecular diagnostic for the detection of an intended target protein within a matter of minutes employing a peptide beacon, the peptide beacon having a stem section having two ends attached to a fluorophore and a quencher and a loop section having a receptor sequence for binding with the intended target protein, the two ends forming a coiled-coil structure when the receptor sequence is unbound with the intended target protein and an open-coil structure when the receptor sequence is bound with the intended target protein, wherein the peptide beacons are able to provide a signal for the detection of the receptor binding domain of the intended target protein, such as SARS-CoV-2 spike protein, by the stem section transitioning from the coiled-coil structure to the open-coil structure that moves the fluorophore away from the quencher, resulting in an increase in the fluorescence yield of the peptide beacon.

Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein. The method may further include contacting the viral particles produced by the first cell with a second cell to which the virus binds in the absence and presence of the compound and measuring the amount of signal produced by the second cell.

The present invention provides a fusion protein comprising an HPV cancer-causing protein segment, a coding sequence thereof and an application thereof in preparing drugs for detecting or treating HPV-related diseases. The fusion protein can simultaneously induce the humoral immunity and the cellular immunity for a high-risk HPV cancer protein and has anti-cancer activity in vivo.

The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.